RESUMEN
In this article, the GEITDAH -the Spanish abbreviation of the Special Interest Group on Attention Deficit Hyper-activity Disorder (ADHD)- presents a consensus reached by experts in the management of ADHD from all over Spain. The consensus concerns fundamental aspects that should be the starting point for future local or regional consensus guides. Another aim of this consensus is also to reduce the amount of variability that occurs in the health care offered to patients with ADHD in our country, as well as to act as a stimulus in educational matters. That fact that it is not very long will make it more popular among greater numbers of people and this will allow these goals to be reached more effectively. The conclusions in the consensus guide have been constructed around an introduction dealing with basic aspects and recommendations for diagnosis, treatment (both pharmacological and psychotherapeutic), patient flow and organisational aspects.
Asunto(s)
Trastorno por Déficit de Atención con Hiperactividad , Consenso , Trastorno por Déficit de Atención con Hiperactividad/diagnóstico , Trastorno por Déficit de Atención con Hiperactividad/terapia , Guías como Asunto , Humanos , Psicoterapia , EspañaRESUMEN
No disponible
Asunto(s)
Humanos , Masculino , Femenino , Niño , Tamizaje Masivo/historia , Tamizaje Masivo/legislación & jurisprudencia , Tamizaje Masivo/métodos , Atención Primaria de Salud/métodos , Atención Primaria de Salud/tendencias , Trastorno Autístico/epidemiología , Trastorno Autístico/terapia , Atención Prenatal/tendencias , Diagnóstico Prenatal/métodos , Diagnóstico Prenatal/normas , Atención Primaria de Salud/organización & administración , Atención Primaria de Salud/estadística & datos numéricos , Trastorno AutísticoRESUMEN
No disponible
No disponible
Asunto(s)
Humanos , Femenino , Niño , Bruxismo/complicaciones , Trastorno Obsesivo Compulsivo/complicaciones , Sertralina/efectos adversos , Buspirona/uso terapéutico , Fluoxetina/uso terapéutico , Paroxetina/uso terapéuticoRESUMEN
OBJECTIVE: To study the clinical benefits and safety of paroxetine (PXT) in a group of patients younger than 14 years old, with a diagnosis of major depressive disorder. METHOD: Patients were recruited from a psychiatric outpatient clinic. They were assessed for disease severity using the Clinical Global Severity (CGS) scale at 1 month, 3 months, and 8 months. Intensity of the therapeutic response (the reduction in CGS) was measured after 1 and 3 months. All patients were given open-label treatment with PXT. RESULTS: At the start of treatment, most patients had "severe" depression (mean CGS score, 3.02). This improved to a score of 2.2 after 1 month and to 1.22 after 3 months of treatment. All patients experienced a complete remission of symptoms by the end of treatment (mean 8.4 months). PXT was well tolerated. Only 4 of the 45 patients experienced (mainly gastrointestinal) side effects; in 3 patients the side effects were of mild severity, and none required withdrawal from the trial. CONCLUSIONS: PXT can be effective in treating major depression and was well tolerated by children younger than 14 years old. This result indicates that PXT should be investigated further in children, in double-blind trials.
Asunto(s)
Antidepresivos/uso terapéutico , Trastorno Depresivo/tratamiento farmacológico , Paroxetina/uso terapéutico , Adolescente , Niño , Femenino , Humanos , MasculinoRESUMEN
The XYY syndrome presents with a wide variation in the clinical features, both of the physical and behavioral nature. We report two new cases which illustrate this statement. The first case presented with aggressive behaviour and cryptorchidism. The second case was associated with pathological short height, pubertal delay and cardiac features (extrasystoles and short PR interval). We revise some of the aspects of XYY syndrome.